VKTX vs. IVV

In the year-to-date period, VKTX achieves a -33.40% return, which is significantly lower than IVV's 0.90% return. Both investments have delivered pretty close results over the past 10 years, with VKTX having a 13.09% annualized return and IVV not far behind at 12.79%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and iShares Core S&P 500 ETF (IVV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VKTX Sharpe Ratio is -0.68, which is lower than the IVV Sharpe Ratio of 0.73. The chart below compares the historical Sharpe Ratios of VKTX and IVV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

VKTX has not paid dividends to shareholders, while IVV's dividend yield for the trailing twelve months is around 1.31%.

The maximum VKTX drawdown since its inception was -90.41%, which is greater than IVV's maximum drawdown of -55.25%. Use the drawdown chart below to compare losses from any high point for VKTX and IVV.

Viking Therapeutics, Inc. (VKTX) has a higher volatility of 16.04% compared to iShares Core S&P 500 ETF (IVV) at 4.82%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than IVV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.